Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey

Cancer Investigation

Volumn 31, Issue 3, 2013, Pages 206-211

  Princewill, Kelechi ^a   Kyere, Sampson ^a   Awan, Omer ^a   Mulligan, Michael ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness research; Detection diagnosis; Myeloma

Indexed keywords

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE RADIOGRAPHY; FEMALE; HUMAN; IMAGING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGIST; RETROSPECTIVE STUDY; WHOLE BODY CT;

ADULT; AGED; BONE AND BONES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84875048901     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2013.764565     Document Type: Article

References (19)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer Statistics. CA Cancer J Clin 2011;61:212-236.
2. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
3. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H,Mehta J,Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B; Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379-398.
4. Durie B.The role of anatomic and functional imaging inmyeloma: description of Durie/Salmon PLUS staging system. Eur J Cancer 2006;42:1539-1543.
5. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23:1545-1556.
6. Baur A, St?abler A, Nagel D, Lamerz R, Bartl R, Hiller E,Wendtner C, Bachner F, ReiserM.Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334-1345.
7. Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen CD, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for followup and therapy response monitoring in patients with multiple myeloma. Cancer 2007;109:1617-1626.
8. Gleeson TG, Moriarty J, Shortt CP, Gleeson JP, Fitzpatrick P, Byrne B, McHugh J, O'Connell M, O'Gorman P, Eustace SJ. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol. 2009; 38:225-236.
9. Orchard K, Barrington S, Buscombe J, Hilson A, Prentice HG, Metha A. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002;117:133-135.
10. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients withmultiplemyeloma. AJR 2005;184:1199-1204.
11. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Wholebody 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-1463.
12. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, Dahmen G, Bockisch A, Debatin JF, Ruehm SG. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA J Am Med Assoc 2003;290:3199-3206.
13. Baur-Melnyk A, Buhmann S, Durr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Rad 2005;55:56-63.
14. Breyer R, Mulligan ME, Smith S, Line B, Badros A. Comparison of FDG PET/CT to other imagingmodalities inmyeloma. Skeletal Radiol 2006 Sept;35(9):632-640.
15. Mahnken AH, Wildberger JE, Gehbauer G, Schmitz-Rode T, Blaum M, Fabry U, G?unther RW. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002;178:1429-1436.
16. Hillengass J, Fechtner K, Weber MA, B?auerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme S, Goldschmidt H. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28:1606-1610.
17. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda- RomanM, MohiuddinA, Yaccoby S, Sawyer J,Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007;25:1121-1128.
18. Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med. 1993;94:57-61.
19. He Y,Wheatley K, ClarkO,Glasmacher A, RossH,Djulbegovic B. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev. 2003;CD004023.